Ethnic differences between Japanese and Caucasians in the expression levels of mRNAs for CYP3A4, CYP3A5 and CYP3A7: Lack of co-regulation of the expression of CYP3A in Japanese livers

Xenobiotica

Volumn 35, Issue 1, 2005, Pages 69-83

  Yamaori, S ^a,d   Yamazaki, H ^a   Iwano, S ^a   Kiyotani, K ^a   Matsumura, K ^a   Saito, T ^a   Parkinson, A ^b   Nakagawa, K ^c   Kamataki, T ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b XenoTech LLC   (United States)

^c KUMAMOTO UNIVERSITY   (Japan)

^d HOKURIKU UNIVERSITY   (Japan)

Author keywords

Adult human liver; Co regulation; Cytochrome P450 3A mRNAs; Racial difference; Real time reverse transcriptase polymerase chain reaction (RT PCR)

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; MESSENGER RNA;

ARTICLE; ASIAN AMERICAN; CAUCASIAN; CONTROLLED STUDY; ENZYME REGULATION; ETHNOLOGY; GENOTYPE; HETEROZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION;

ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; COMPUTER SYSTEMS; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENETIC SCREENING; HUMANS; LIVER; OXIDOREDUCTASES, N-DEMETHYLATING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

STAPHYLOCOCCUS PHAGE 3A;

EID: 16244368066     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250400021796     Document Type: Article

References (40)

1. Aoyama T, Yamano S, Waxman DJ, Lapenson DP, Meyer UA, Fischer V, Tyndale R, Inaba T, Kalow W, Gelboin HV, Gonzalez FJ. 1989. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. Journal of Biological Chemistry 264:10388-10395.
2. Bombail V, Taylor K, Gibson GG, Plant N. 2004. Role of Sp1, C/EBPα, HNF3, and PXR in the basal- and xenobiotic-mediated regulation of the CYP3A4 gene. Drug Metabolism and Disposition 32:525-535.
3. Burk O, Koch I, Raucy J, Hustert E, Eichelbaum M, Brockmöller J, Zanger UM, Wojnowski L. 2004. The induction of CYP3A5 in human liver and intestine is mediated by the xenobiotic sensors PXR and CAR. Journal of Biological Chemistry 279:38379-38385.
4. Burk O, Tegude H, Koch I, Husten E, Wolbold R, Glaeser H, Klein K, Fromm MF, Nuessler AK, Neuhaus P, Zanger UM, Eichelbaum M, Wojnowski L. 2002. Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine. Journal of Biological Chemistry 277:24280-24288.
5. Dai D, Tang J, Rose R, Hodgson E, Bienstock RJ, Mohrenweiser HW, Goldstein JA. 2001. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. Journal of Pharmacology and Experimental Therapeutics 299:825-831.
6. Fukuen S, Fukuda T, Maune H, Ikenaga Y, Yamamoto I, Inaba T, Azuma J. 2002. Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5 *3 and *6, in a Japanese population. Pharmacogenetics 12:331-334.
7. Fukushima-Uesaka H, Saito Y, Watanabe H, Shiseki K, Saeki M, Nakamura T, Kurose K, Sai K, Komamura K, Ueno K, Kamakura S, Kitakaze M, Hanai S, Nakajima T, Matsumoto K, Saito H, Goto Y, Kimura H, Katoh M, Sugai K, Minami N, Shirao K, Tamura T, Yamamoto N, Minami H, Ohtsu A, Yoshida T, Saijo N, Kitamura Y, Kamatani N, Ozawa S, Sawada J. 2004. Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Human Mutation 23:100.
8. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, Waxman DJ. 1986. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. Journal of Biological Chemistry 261:5051-5060.
9. Inoue E, Takahashi Y, Imai Y, Kamataki T. 2000. Development of bacterial expression system with high yield of CYP3A7, a human fetus-specific form of cytochrome P450. Biochemical and Biophysical Research Communications 269:623-627.
10. Inoue K, Yamazaki H, Imiya K, Akasaka S, Guengerich FP, Shimada T. 1997. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics 7:103-113.
11. Iwano S, Saito T, Takahashi Y, Fujita K, Kamataki T. 2001. Cooperative regulation of CYP3A5 gene transcription by NF-Y and Sp family members. Biochemical and Biophysical Research Communications 286:55-60.
12. Iwata H, Fujita K, Kushida H, Suzuki A, Konno Y, Nakamura K, Fujino A, Kamataki T. 1998. High catalytic activity of human cytochrome P450 co-expressed with human NADPH-cytochrome P450 reductase in Escherichia coli. Biochemical Pharmacology 55:1315-1325.
13. Kitada M, Kamataki T, Itahashi K, Rikihisa T, Kato R, Kanakubo Y. 1985. Purification and properties of cytochrome P-450 from homogenates of human fetal livers. Archives of Biochemistry and Biophysics 241:275-280.
14. 1 by P-450 HFLa in human fetal livers. Mutation Research 227:53-58.
15. Kiyotani K, Yamazaki H, Fujieda M, Iwano S, Matsumura K, Satarug S, Ujjin P, Shimada T, Guengerich FP, Parkinson A, Honda G, Nakagawa K, Ishizaki T, Kamataki T. 2003. Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6 *9). Pharmacogenetics 13:689-695.
16. Koch I, Weil R, Wolbold R, Brockmöller J, Hustert E, Burk O, Nuessler AK, Neuhaus P, Eichelbaum M, Zanger U, Wojnowski L. 2002. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metabolism and Disposition 30:1108-1114.
17. Komori M, Nishio K, Kitada M, Shiramatsu K, Muroya K, Soma M, Nagashima K, Kamataki T. 1990. Fetus-specific expression of a form of cytochrome P-450 in human livers. Biochemistry 29:4430-4433.
18. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E. 2001. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genetics 27:383-391.
19. Lamba JK, Lin YS, Thummel K, Daly A, Watkins PB, Strom S, Zhang J, Schuetz EG. 2002. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 12:121-132.
20. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, Thummel KE. 2002. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Molecular Pharmacology 62:162-172.
21. Matsumura K, Saito T, Takahashi Y, Ozeki T, Kiyotani K, Fujieda M, Yamazaki H, Kunitoh H, Kamataki T. 2004. Identification of a novel polymorphic enhancer of the human CYP3A4 gene. Molecular Pharmacology 65:326-334.
22. Molowa DT, Schuetz EG, Wrighton SA, Watkins PB, Kremers P, Mendez-Picon G, Parker GA, Guzelian PS. 1986. Complete cDNA sequence of a cytochrome P-450 inducible by glucocorticoids in human liver. Proceedings of the National Academy of Sciences, USA 83:5311-5315.
23. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW. 1996. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1-42.
24. Özdemir V, Kalowa W, Tang BK, Paterson AD, Walker SE, Endrenyi L, Kashuba AD. 2000. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10:373-388.
25. Pascussi JM, Drocourt L, Gerbal-Chaloin S, Fabre JM, Maurel P, Vilarem MJ. 2001. Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor. European Journal of Biochemistry 268:6346-6358.
26. Rendic S. 2002. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metabolism Reviews 34:383-448.
27. Rodríguez-Antona C, Donato MT, Pareja E, Gómez- Lechón MJ, Castell JV. 2001. Cytochrome P-450 mRNA expression in human liver and its relationship at enzyme activity. Archives of Biochemistry and Biophysics 393:308-315.
28. Saito T, Takahashi Y, Hashimoto H, Kamataki T. 2001. Novel transcriptional regulation of the human CYP3A7 gene by Sp1 and Sp3 through nuclear factor κB-like element. Journal of Biological Chemistry 276:38010-38022.
29. Schuetz JD, Beach DL, Guzelian PS. 1994. Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics 4:11-20.
30. NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver. Proceedings of the National Academy of Sciences, USA 86:462-465.
31. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. 1994. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics 270:414-423.
32. 1 in the rat. Drug Metabolism and Disposition 22:383-391.
33. Tateishi T, Watanabe M, Moriya H, Yamaguchi S, Sato T, Kobayashi S. 1999. No ethnic difference between Caucasian and Japanese hepatic samples in the expression frequency of CYP3A5 and CYP3A7 proteins. Biochemical Pharmacology 57:935-939.
34. Westlind A, Malmebo S, Johansson I, Otter C, Andersson TB, Ingelman-Sundberg M, Oscarson M. 2001. Cloning and tissue distribution of a novel human cytochrome P450 of the CYP3A subfamily, CYP3A43. Biochemical and Biophysical Research Communications 281:1349-1355.
35. Westlind-Johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson I, Edwards RJ, Boobis AR, Ingelman-Sundberg M. 2003. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metabolism and Disposition 31:755-761.
36. Wolbold R, Klein K, Burk O, Nussler AK, Neuhaus P, Eichelbaum M, Schwab M, Zanger UM. 2003. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38:978-988.
37. Wrighton SA, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL, Molowa DT, VandenBranden M. 1990. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Molecular Pharmacology 38:207-213.
38. Wrighton SA, Ring BJ, Watkins PB, VandenBranden M. 1989. Identification of a polymorphically expressed member of the human cytochrome P-450III family. Molecular Pharmacology 36:97-105.
39. Yamaori S, Yamazaki H, Iwano S, Kiyotani K, Matsumura K, Honda G, Nakagawa K, Ishizaki T, Kamataki T. 2004. CYP3A5 contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects. Drug Metabolism and Pharmacokinetics 19:120-129.
40. 5 on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7. Biochemical Pharmacology 66:2333-2340.